{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/prescribing-information/topical-beta-blockers/","result":{"pageContext":{"chapter":{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers","depth":2,"htmlHeader":"<!-- begin field 8e5411b0-5a68-4301-9421-d5cf88ae8d9b --><h2>Topical beta-blockers</h2><!-- end field 8e5411b0-5a68-4301-9421-d5cf88ae8d9b -->","summary":"","htmlStringContent":"<!-- begin item 4e12e032-8aa5-4c55-af69-925f68cec73f --><!-- end item 4e12e032-8aa5-4c55-af69-925f68cec73f -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"61472daf-2b3c-5162-be17-2b82a9cf8f15","slug":"available-preparations","fullItemName":"Available preparations","depth":3,"htmlHeader":"<!-- begin field db84d889-8fb5-4bbc-8fb3-553a81e6306c --><h3>Which topical beta-blockers are available for the treatment of glaucoma?</h3><!-- end field db84d889-8fb5-4bbc-8fb3-553a81e6306c -->","summary":"","htmlStringContent":"<!-- begin item b5163b3d-7a0b-44a3-bf56-eacba4646f47 --><!-- begin field 8b3f5d22-4030-4290-97d8-d5455fec6b9a --><ul><li><strong>Topical beta-blocker eye drops available for the treatment of glaucoma</strong><strong> are:</strong><ul><li>Betaxolol. Usual dose is one drop twice daily.</li><li>Levobunolol. Usual dose is one drop once or twice daily.</li><li>Timolol. Usual dose is one drop once or twice daily. Timolol is also available as long-acting once-daily topical preparations.</li></ul></li><li><strong>Preservative-free preparations</strong> (without benzalkonium chloride) of betaxolol, levobunolol, and timolol eye drops are available. These are more expensive than the standard preparations but may be prescribed by an ophthalmologist to a person with an allergy to benzalkonium chloride.</li><li><strong>Combination preparations with </strong>prostaglandin analogues, sympathomimetics, and carbonic anhydrase inhibitors are available.</li><li><strong>Topical beta-blocker eye drops are not licensed for children under 18 years of age.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 8b3f5d22-4030-4290-97d8-d5455fec6b9a --><!-- end item b5163b3d-7a0b-44a3-bf56-eacba4646f47 -->","subChapters":[]},{"id":"884fc8ba-f48b-5366-aae8-8cf7e32dc6dd","slug":"action","fullItemName":"Action","depth":3,"htmlHeader":"<!-- begin field 6c12a69f-5f0e-45d1-824a-562f269c1cc2 --><h3>How do topical beta-blockers work?</h3><!-- end field 6c12a69f-5f0e-45d1-824a-562f269c1cc2 -->","summary":"","htmlStringContent":"<!-- begin item 232e8aa7-eb4d-4eba-a15c-66fbb6c97439 --><!-- begin field daf49de7-524e-46d3-b9fc-eb69c23783c7 --><ul><li>Topical beta-blockers reduce intraocular pressure (IOP) by decreasing the rate of production of aqueous humour.</li><li>Oral beta-blockers also reduce IOP, but they are not used primarily to treat or prevent glaucoma because of the risk of systemic adverse effects.<ul><li>There may be little added effect on IOP if a topical beta-blocker eye preparation is added to a person already taking an oral beta-blocker for another condition. However, the combination may increase the risk of developing adverse effects.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>]</p><!-- end field daf49de7-524e-46d3-b9fc-eb69c23783c7 --><!-- end item 232e8aa7-eb4d-4eba-a15c-66fbb6c97439 -->","subChapters":[]},{"id":"fd431d42-3f0f-523a-94be-b3aef08a4957","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7c72a12d-2e56-4fe4-a194-9f262c0c8c96 --><h3>What key adverse effects are associated with topical beta-blockers?</h3><!-- end field 7c72a12d-2e56-4fe4-a194-9f262c0c8c96 -->","summary":"","htmlStringContent":"<!-- begin item c7e9c8d2-a2b2-45db-871a-42d862c67abf --><!-- begin field 32bd8e0e-636b-4d39-ad73-09fad732dc69 --><ul><li><strong>Local adverse effects</strong><ul><li>Local adverse effects are common and include burning, stinging, pain, itching, redness, dry eyes, and allergic reactions to the active drug or preservatives.</li><li>Less common local adverse effects are blepharoconjunctivitis and corneal disorders.</li></ul></li><li><strong>Systemic adverse effects</strong><ul><li>Systemic absorption can follow topical application with beta-blocker eye drops. Common or very common systemic adverse effects with all beta-blockers include: abdominal discomfort, bradycardia, confusion, depression, diarrhoea, dizziness, dry eye, dyspnoea, erectile dysfunction, fatigue, headache, heart failure, nausea, paraesthesia, peripheral coldness, peripheral vascular disease, rash, sleep disorders, syncope, visual impairment, and vomiting. For further detailed information on possible adverse effects see the <a class=\"topic-reference external-reference\" href=\"/topics/angina/prescribing-information/beta-blockers/\">prescribing information</a> section on beta-blockers in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 32bd8e0e-636b-4d39-ad73-09fad732dc69 --><!-- end item c7e9c8d2-a2b2-45db-871a-42d862c67abf -->","subChapters":[]},{"id":"73f58207-6777-51c0-a67b-359e1cc90014","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field 7dcd9549-acbe-4e5b-b1ab-a94bb15c9dd5 --><h3>What drug interactions are important with topical beta-blockers?</h3><!-- end field 7dcd9549-acbe-4e5b-b1ab-a94bb15c9dd5 -->","summary":"","htmlStringContent":"<!-- begin item 16e571db-acd5-4b37-851a-959b7da3c56d --><!-- begin field bd8f1c01-5b73-4c75-94fd-e6773da576b2 --><ul><li>Mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020e</a>].</li><li>Systemic absorption can follow topical application with beta-blocker eye drops. <ul><li>For detailed information on possible drug interactions following systemic absorption, see the <a class=\"topic-reference external-reference\" href=\"/topics/angina/prescribing-information/beta-blockers/\">Prescribing information</a> section on beta-blockers in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>.</li></ul></li></ul><!-- end field bd8f1c01-5b73-4c75-94fd-e6773da576b2 --><!-- end item 16e571db-acd5-4b37-851a-959b7da3c56d -->","subChapters":[]},{"id":"b6bff997-c507-5ddf-9443-804266ad4aaf","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 805ce7c4-dfbe-42f4-a171-f883e116d68c --><h3>What are the cautions and contraindications when prescribing topical beta-blockers?</h3><!-- end field 805ce7c4-dfbe-42f4-a171-f883e116d68c -->","summary":"","htmlStringContent":"<!-- begin item 7ebfe753-bda9-48a6-98f5-8e38416347db --><!-- begin field 39fdd281-c8eb-46a7-838b-0c7e3636ab24 --><ul><li>Use topical beta-blockers with caution in people with corneal disease. </li><li>Systemic absorption can follow topical application with beta-blocker eye drops. Therefore, the cautions and contraindications are similar as for oral beta-blockers. For detailed information see the <a class=\"topic-reference external-reference\" href=\"/topics/angina/prescribing-information/beta-blockers/\">Prescribing information</a> section in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 39fdd281-c8eb-46a7-838b-0c7e3636ab24 --><!-- end item 7ebfe753-bda9-48a6-98f5-8e38416347db -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}